SOUTH SAN FRANCISCO, Calif.,
July 25, 2017 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it
will report its second quarter financial results after market close
on Tuesday, August 1, 2017.
Rigel senior management will follow the announcement with a live
conference call and webcast at 5:00pm
Eastern Time (2:00pm Pacific
Time) to discuss the financial results and provide a company
update.
Participants can access the live conference call by dialing
855-892-1489 (domestic) or 720-634-2939 (international) and using
the Conference ID number 55352069. The conference call will
also be webcast live and can be accessed from Rigel's website at
www.rigel.com. The webcast will be archived and available for
replay after the call via the Rigel website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc. is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematological disorders, cancer and rare diseases. Rigel's
pioneering research focuses on signaling pathways that are critical
to disease mechanisms. The company's current clinical programs
include clinical trials of fostamatinib, an oral spleen tyrosine
kinase (SYK) inhibitor, in a number of indications. Rigel has
submitted an NDA to the FDA for fostamatinib in patients with
chronic or persistent immune thrombocytopenia (ITP). In addition,
Rigel has product candidates in development with partners BerGenBio
AS, Daiichi Sankyo and Aclaris Therapeutics.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
Media Contact: Jessica Daitch,
Inventiv Health PR Group
Phone: 917.816.6712
Email: Jessica.daitch@inventivhealth.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2017-financial-results-300493276.html
SOURCE Rigel Pharmaceuticals, Inc.